Pallando Therapeutics is an early-stage biotechnology company developing next-generation targeted protein degraders with an emphasis on precision targeting, under the tagline "Intelligent Degradation, Innovative Therapies." It was surfaced as a portfolio company of General Catalyst and added to the API Evangelist network. - View it on GitHub